Mechanisms of disease: Psoriasis

New England Journal of Medicine

Volumn 361, Issue 5, 2009, Pages

  Nestle, Frank O ^a,c   Kaplan, Daniel H ^b   Barker, Jonathan ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; BETA DEFENSIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CYTOKINE; EFALIZUMAB; ETANERCEPT; IMIQUIMOD; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 23; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; METHOXSALEN; POLYPEPTIDE ANTIBIOTIC AGENT; PSORIASIN; TUMOR NECROSIS FACTOR ALPHA; USTEKINUMAB; VASCULOTROPIN; ZINC FINGER PROTEIN;

ACANTHOSIS; ADAPTIVE IMMUNITY; ARTHROPATHY; BIOLOGICAL THERAPY; CARDIOVASCULAR RISK; CELL INTERACTION; CELL MATURATION; CHROMOSOMAL LOCALIZATION; CHROMOSOME 6P; CROHN DISEASE; CYTOKINE PRODUCTION; DENDRITIC CELL; DEPRESSION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GENE EXPRESSION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC ENGINEERING; GENETIC LINKAGE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HEALTH CARE COST; HEART INFARCTION; HEREDITY; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; IMMUNOTHERAPY; INCIDENCE; INNATE IMMUNITY; KERATINOCYTE; KNOCKOUT MOUSE; LYMPHOMA; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; METABOLIC SYNDROME X; MICROVASCULATURE; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARAKERATOSIS; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUVA; QUALITY OF LIFE; REGULATORY T LYMPHOCYTE; REVIEW; RISK BENEFIT ANALYSIS; SKIN CANCER; SKIN INFLAMMATION; SPONTANEOUS MUTATION; STRESS; T LYMPHOCYTE; TH2 CELL; TRANSGENIC MOUSE; XENOTRANSPLANTATION; ANIMAL; DISEASE MODEL; GENETICS; IMMUNOLOGY; PATHOLOGY; PHYSIOLOGY; SKIN;

ANIMALS; BIOLOGICAL THERAPY; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; GENOME-WIDE ASSOCIATION STUDY; HUMANS; IMMUNITY, INNATE; KERATINOCYTES; PSORIASIS; SKIN; T-LYMPHOCYTES;

EID: 68049131637     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra0804595     Document Type: Article

References (100)

1. Bateman T. Practical synopsis of cutaneous diseases, according to the arrangement of Dr. Willan: exhibiting a concise view of the diagnostic symptoms and the method of treatment. London: Longman, Rees, Orme, Brown, Green, & Longman, 1836.
2. Christophers E. Psoriasis - epidemiology and clinical spectrum. Clin Exp Dermatol 2001;26:314-320
3. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007;370:263-271
4. Horn EJ, Fox KM, Patel V, Chiou CF, Dann F, Lebwohl M. Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol 2007;57:963-971 (Pubitemid 350087343)
5. Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 2004;51:704-708 (Pubitemid 39516879)
6. Christensen TE, Callis KP, Papenfuss J, et al. Observations of psoriasis in the absence of therapeutic intervention identifies two unappreciated morphologic variants, thin-plaque and thick-plaque psoriasis, and their associated phenotypes. J Invest Dermatol 2006;126:2397-2403 (Pubitemid 44582260)
7. Farber EM, Nall ML. The natural his tory of psoriasis in 5,600 patients. Dermatologica 1974;148:1-18.
8. Trembath RC, Clough RL, Rosbotham JL, et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 1997;6:813-820
9. Nair RP, Duffin KC, Helms C, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaβ pathways. Nat Genet 2009;41:199-204.
10. Nair RP, Henseler T, Jenisch S, et al. Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum Mol Genet 1997;6:1349-1356 (Pubitemid 27351077)
11. Helms C, Cao L, Krueger JG, et al. A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat Genet 2003;35:349-356 (Pubitemid 37486918)
12. Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007;80:273-290 (Pubitemid 46175676)
13. Capon F, Di Meglio P, Szaub J, et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet 2007;122:201-206 (Pubitemid 47241785)
14. Tsunemi Y, Saeki H, Nakamura K, et al. Interleukin-12 p40 gene (IL12B) 3′-untranslated region polymorphism is associated with susceptibility to atopic dermatitis and psoriasis vulgaris. J Dermatol Sci 2002;30:161-166 (Pubitemid 36159027)
15. Rahman P, Inman RD, Maksymowych WP, Reeve JP, Peddle L, Gladman DD. Association of interleukin 23 receptor variants with psoriatic arthritis. J Rheumatol 2009;36:137-140
16. Rahman P, Inman RD, Gladman DD, Reeve JP, Peddle L, Maksymowych WP. Association of interleukin-23 receptor variants with ankylosing spondylitis. Arthritis Rheum 2008;58:1020-1025 (Pubitemid 351564003)
17. Burton PR, Clayton DG, Cardon LR, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007;39:1329-1337
18. Capon F, Bijlmakers MJ, Wolf N, et al. Identification of ZNF313/RNF114 as a novel psoriasis susceptibility gene. Hum Mol Genet 2008;17:1938-1945 (Pubitemid 351865842)
19. Wolf N, Quaranta M, Prescott NJ, et al. Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. J Med Genet 2008;45:114-116 (Pubitemid 351252875)
20. Li Y, Liao W, Chang M, et al. Further genetic evidence for three psoriasis-risk genes: ADAM33, CDKAL1, and PTPN22. J Invest Dermatol 2009;129:629-634
21. Hüffmeier U, Steffens M, Burkhardt H, et al. Evidence for susceptibility determinant(s) to psoriasis vulgaris in or near PTPN22 in German patients. J Med Genet 2006;43:517-522 (Pubitemid 43927327)
22. Smith RL, Warren RB, Eyre S, et al. Polymorphisms in the PTPN22 region are associated with psoriasis of early onset. Br J Dermatol 2008;158:962-968
23. Chang M, Li Y, Yan C, et al. Variants in the 5q31 cytokine gene cluster are associated with psoriasis. Genes Immun 2008;9:176-181 (Pubitemid 351351659)
24. de Cid R, Riveira-Munoz E, Zeeuwen PL, et al. Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nat Genet 2009;41:211-215
25. Zhang XJ, Huang W, Yang S, et al. Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q2. Nat Genet 2009;41:205-210
26. Bowcock AM, Krueger JG. Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol 2005;5:699-711. [Erratum, Nat Rev Immunol 2005;5:826.]
27. Capon F, Munro M, Barker J, Trembath R. Searching for the major histocompatibility complex psoriasis susceptibility gene. J Invest Dermatol 2002;118:745-751 (Pubitemid 34526535)
28. Asumalahti K, Laitinen T, Itkonen-Vatjus R, et al. A candidate gene for psoriasis near HLA-C, HCR (Pg8), is highly polymorphic with a disease-associated susceptibility allele. Hum Mol Genet 2000;9:1533-1542 [Erratum, Hum Mol Genet 2001;10:301.]
29. Allen MH, Veal C, Faassen A, et al. A non-HLA gene within the MHC in psoriasis. Lancet 1999;353:1589-1590 (Pubitemid 29219215)
30. Nair RP, Stuart PE, Nistor I, et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 2006;78:827-851
31. Asumalahti K, Ameen M, Suomela S, et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Invest Dermatol 2003;120:627-632 (Pubitemid 36344006)
32. Allen MH, Ameen H, Veal C, et al. The major psoriasis susceptibility locus PSORS1 is not a risk factor for late-onset psoriasis. J Invest Dermatol 2005;124:103-106 (Pubitemid 40100955)
33. Liu Y, Helms C, Liao W, et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 2008;4(3):e1000041. (Pubitemid 351656703)
34. Hollox EJ, Huffmeier U, Zeeuwen PL, et al. Psoriasis is associated with increased beta-defensin genomic copy number. Nat Genet 2008;40:23-25
35. Yao Y, Richman L, Morehouse C, et al. Type I interferon: potential therapeutic target for psoriasis? PLoS One 2008;3(7):e2737. [Erratum, PLoS ONE 2009;4(3).]
36. Haider AS, Lowes MA, Suàrez-Fariñas M, et al. Cellular genomic maps help dissect pathology in human skin disease. J Invest Dermatol 2008;128:606-615 (Pubitemid 351252667)
37. Sonkoly E, Wei T, Janson PC, et al. MicroRNAs: novel regulators involved in the pathogenesis of psoriasis? PLoS One 2007;2(7):e610.
38. Braun-Falco O, Burg G. Inflammatory infiltrate in psoriasis vulgaris: a cytochemical study. Arch Klin Exp Dermatol 1970;236:297-314. (In German.)
39. Bos JD, Hulsebosch HJ, Krieg SR, Bakker PM, Cormane RH. Immunocompetent cells in psoriasis: in situ immunophenotyping by monoclonal antibodies. Arch Dermatol Res 1983;275:181-189
40. Nestle FO, Nickoloff BJ. Role of dendritic cells in benign and malignant lymphocytic infiltrates of the skin. Dermatol Clin 1994;12:271-282
41. Menssen A, Trommler P, Vollmer S, et al. Evidence for an antigen-specific cellular immune response in skin lesions of patients with psoriasis vulgaris. J Immunol 1995;155:4078-4083
42. Nestle FO, Nickoloff BJ. From classical mouse models of psoriasis to a spontaneous xenograft model featuring use of AGR mice. Ernst Schering Res Found Workshop 2005;50:203-212
43. Griffiths CE, Powles AV, Leonard JN, Fry L, Baker BS, Valdimarsson H. Clearance of psoriasis with low dose cyclosporin. Br Med J (Clin Res Ed) 1986;293:731-732 (Pubitemid 16025288)
44. Prinz J, Braun-Falco O, Meurer M, et al. Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis. Lancet 1991;338:320-321
45. Eedy DJ, Burrows D, Bridges JM, Jones FG. Clearance of severe psoriasis after allogenic bone marrow transplantation. BMJ 1990;300:908. (Pubitemid 20145789)
46. Gardembas-Pain M, Ifrah N, Foussard C, Boasson M, Saint Andre JP, Verret JL. Psoriasis after allogeneic bone marrow transplantation. Arch Dermatol 1990;126:1523. (Pubitemid 20367701)
47. Schön MP, Boehncke W-H. Psoriasis. N Engl J Med 2005;352:1899-1912
48. Nickoloff BJ. Skin innate immune system in psoriasis: friend or foe? J Clin Invest 1999;104:1161-1164
49. Funk J, Langeland T, Schrumpf E, Hanssen LE. Psoriasis induced by interferon-alpha. Br J Dermatol 1991;125:463-465
50. Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005;202:135-143 (Pubitemid 41002916)
51. Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007;449:564-569 (Pubitemid 47525141)
52. Büchau AS, Gallo RL. Innate immunity and antimicrobial defense systems in psoriasis. Clin Dermatol 2007;25:616-624
53. Nestle FO, Turka LA, Nickoloff BJ. Characterization of dermal dendritic cells in psoriasis: autostimulation of T lymphocytes and induction of Th1 type cytokines. J Clin Invest 1994;94:202-209 (Pubitemid 24218093)
54. Lowes MA, Chamian F, Abello MV, et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A 2005;102:19057-19062 (Pubitemid 43049565)
55. Chamian F, Lowes MA, Lin SL, et al. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci U S A 2005;102:2075-2080 (Pubitemid 40262014)
56. Wang H, Peters T, Kess D, et al. Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. J Clin Invest 2006;116:2105-2114 (Pubitemid 44162319)
57. Stratis A, Pasparakis M, Rupec RA, et al. Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation. J Clin Invest 2006;116:2094-2104 (Pubitemid 44162318)
58. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med 2001;345:340-350
59. Conrad C, Boyman O, Tonel G, et al. Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat Med 2007;13:836-842
60. Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 1993;101:701-705 (Pubitemid 23322027)
61. Teunissen MB, Koomen CW, de Waal Malefyt R, Wierenga EA, Bos JD. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998;111:645-649
62. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008;128:1207-1211 (Pubitemid 351543220)
63. Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007;445:648-651 (Pubitemid 46232884)
64. Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007;204:3183-3194 [Erratum, J Exp Med 2008;205:1941.]
65. Nickoloff BJ. The cytokine network in psoriasis. Arch Dermatol 1991;127:871-884
66. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367-1374 (Pubitemid 41443403)
67. Liu J, Marino MW, Wong G, et al. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med 1998;4:78-83. (Pubitemid 28133083)
68. Kelchtermans H, Billiau A, Matthys P. How interferon-gamma keeps autoimmune diseases in check. Trends Immunol 2008;29:479-486
69. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008;59:996-1001.
70. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004;199:125-130 (Pubitemid 38076484)
71. Haider AS, Lowes MA, Suàrez-Fariñas M, et al. Identification of cellular pathways of "type 1," Th17 T cells, and TNF-and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis. J Immunol 2008;180:1913-1920.
72. Sugiyama H, Gyulai R, Toichi E, et al. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 2005;174:164-173 (Pubitemid 40007402)
73. Wang H, Peters T, Sindrilaru A, et al. TGF-beta-dependent suppressive function of Tregs requires wild-type levels of CD18 in a mouse model of psoriasis. J Clin Invest 2008;118:2629-2639 (Pubitemid 351949790)
74. Asadullah K, Sabat R, Friedrich M, Volk HD, Sterry W. Interleukin-10: an important immunoregulatory cytokine with major impact on psoriasis. Curr Drug Targets Inflamm Allergy 2004;3:185-192 (Pubitemid 38832749)
75. Detmar M, Brown LF, Claffey KP, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994;180:1141-1146 (Pubitemid 24256627)
76. Young HS, Summers AM, Read IR, et al. Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. J Invest Dermatol 2006;126:453-459
77. Halin C, Fahrngruber H, Meingassner JG, et al. Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor. Am J Pathol 2008;173:265-277 (Pubitemid 351947973)
78. Gudjonsson JE, Johnston A, Dyson M, Valdimarsson H, Elder JT. Mouse models of psoriasis. J Invest Dermatol 2007;127:1292-1308
79. Schön MP. Animal models of psoriasis: a critical appraisal. Exp Dermatol 2008;17:703-712
80. van der Fits L, Mourits S, Voerman JS, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 2009;182:5836-5845
81. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;445:866-873
82. Boyman O, Conrad C, Tonel G, Gilliet M, Nestle FO. The pathogenic role of tissue-resident immune cells in psoriasis. Trends Immunol 2007;28:51-57 (Pubitemid 46176734)
83. Boehncke WH, Schön MP. Animal models of psoriasis. Clin Dermatol 2007;25:596-605.
84. Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006;126:2194-2201
85. Ravindran V, Scott DL, Choy EH. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann Rheum Dis 2008;67:855-859 (Pubitemid 351829388)
86. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007;157:68-73. (Pubitemid 46934281)
87. Ludwig RJ, Herzog C, Rostock A, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007;156:271-276 (Pubitemid 46095954)
88. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-1741 (Pubitemid 44547793)
89. Mrowietz U, Elder JT, Barker J. The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch Dermatol Res 2006;298:309-319 (Pubitemid 44777679)
90. Nijsten T, Margolis DJ, Feldman SR, Rolstad T, Stern RS. Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. J Am Acad Dermatol 2005;52:434-444
91. Granstein RD. New treatments for psoriasis. N Engl J Med 2001;345:284-287
92. Kupper TS. Immunologic targets in psoriasis. N Engl J Med 2003;349:1987-1990
93. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345:248-255
94. Sterry W, Barker J, Boehncke WH, et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol 2004;151:Suppl 69:3-17. (Pubitemid 39215184)
95. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-1674 [Erratum, Lancet 2008;371:1838.]
96. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-1684 (Pubitemid 351671884)
97. Kimball AB, Gordon KB, Langley RG, Menter A, Chartash EK, Valdes J. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 2008;144:200-207 (Pubitemid 351287002)
98. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009;373:633-640 [Erratum, Lancet 2009;373:1340.]
99. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008;158:558-566 (Pubitemid 351239154)
100. Gladman DD, Rahman P, Krueger GG, et al. Clinical and genetic registries in psoriatic disease. J Rheumatol 2008;35:1458-1463 (Pubitemid 352000804)